Top 50 Biotech Startup Investors in Oceania (August 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Uniseed
VC Fund
|
27 | Australia, United States, United Kingdom | Series A, Seed, Series B | Biotechnology, Manufacturing, Health Care | $471k–$22M |
|
Brandon Capital
VC Fund
|
20 | Australia, United Kingdom, United States | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $673k–$81M |
|
Uniseed Ventures
VC Fund
|
18 | Australia, United States, United Kingdom | Series A, Seed | Biotechnology, Health Care, Manufacturing | $381k–$16M |
|
Artesian VC
VC Fund
|
13 | Australia, United States, Hong Kong | Seed, Series A, Pre-Seed | Software, Artificial Intelligence, Health Care | $70k–$15M |
|
Icehouse Ventures
VC Fund
|
12 | New Zealand, United States, United Kingdom | Seed, Series A | Software, SaaS, Information Technology | $650k–$19M |
|
Main Sequence Ventures
VC Fund
|
11 | Australia, United States, Philippines | Seed, Series A, Series B | Software, Artificial Intelligence, Manufacturing | $1M–$72M |
|
Medical Research Commercialisation Fund (MRCF)
VC Fund
|
10 | Australia, United Kingdom, United States | Series A, Seed | Biotechnology, Health Care, Medical | $1.3M–$13M |
|
Finistere Ventures
VC Fund
|
9 | United States, New Zealand, Israel | Series B, Series C, Series A | Biotechnology, Agriculture, Food and Beverage | $3.5M–$45M |
|
Callaghan Innovation
VC Fund
|
8 | New Zealand, Australia, United States | Grant, Seed, Pre-Seed | Manufacturing, Software, Information Technology | $5.7k–$1M |
|
Stoic VC
VC Fund
|
8 | Australia, United States, United Kingdom | Seed, Series A | Biotechnology, Medical, Health Care | $600k–$16M |
|
Pacific Channel
VC Fund
|
8 | New Zealand, Australia, United States | Seed, Venture - Series Unknown, Pre-Seed | Manufacturing, Health Care, Biotechnology | $511k–$5.5M |
|
Matū Group
VC Fund
|
8 | New Zealand, Australia, United States | Seed, Pre-Seed, Series A | Biotechnology, Health Care, Manufacturing | $337k–$25M |
|
Melbourne Angels
VC Fund
|
7 | Australia, United States, New Zealand | Seed, Angel | Biotechnology, Software, Information Technology | $34k–$1.3M |
|
OurCrowd
VC Fund
|
7 | Israel, United States, New Zealand | Series B, Series A, Seed | Software, Artificial Intelligence, Health Care | $593k–$65M |
|
Horizons Ventures
VC Fund
|
6 | United States, United Kingdom, Canada | Series A, Series B, Seed | Biotechnology, Software, Artificial Intelligence | $1M–$110M |
|
Flying Fox Ventures
VC Fund
|
6 | Australia, New Zealand, United States | Seed, Series A, Pre-Seed | Software, Artificial Intelligence, Information Technology | $120k–$11M |
|
K1W1
VC Fund
|
6 | New Zealand, United States | Seed, Series A | Software, Manufacturing, Artificial Intelligence | $520k–$18M |
|
Enterprise Angels
VC Fund
|
6 | New Zealand, United States, United Kingdom | Seed, Angel | Software, Information Technology, Health Care | $229k–$4.3M |
|
Fonterra Co-operative Group
VC Fund
|
6 | New Zealand, United States, Germany | Seed, Pre-Seed, Series B | Biotechnology, Food and Beverage, Wellness | $151k–$17M |
|
Brisbane Angels
VC Fund
|
6 | Australia, United States, New Zealand | Seed, Pre-Seed, Series A | Software, Information Technology, Health Care | $200k–$19M |
|
New Zealand Venture Investment Fund
VC Fund
|
5 | New Zealand, United States, Japan | Seed, Series A, Angel | Software, Biotechnology, SaaS | $400k–$8.8M |
|
Australian Medical Angels
VC Fund
|
5 | Australia, Hong Kong, Singapore | Seed, Pre-Seed, Series A | Health Care, Medical, Software | $7k–$3.5M |
|
Sydney Angels
VC Fund
|
5 | Australia, United States | Seed, Angel, Pre-Seed | Software, SaaS, Health Care | $120k–$1.5M |
|
Uniservices
VC Fund
|
5 | New Zealand, United States, United Kingdom | Seed, Pre-Seed, Venture - Series Unknown | Health Care, Medical Device, Manufacturing | $283k–$8.4M |
|
IP Group
VC Fund
|
5 | United Kingdom, United States, Australia | Seed, Series A | Health Care, Biotechnology, Therapeutics | $393k–$30M |
|
IP Group Australia
VC Fund
|
5 | Australia, New Zealand | Seed, Series A, Pre-Seed | Biotechnology, Manufacturing, Renewable Energy | $811k–$30M |
|
Booster
VC Fund
|
5 | New Zealand, United States | Seed, Pre-Seed, Venture - Series Unknown | Biotechnology, Manufacturing, Medical Device | $157k–$6.1M |
|
Possible Ventures
VC Fund
|
4 | Germany, United States, Australia | Seed, Pre-Seed, Series A | Software, Biotechnology, Information Technology | $586k–$47M |
|
Breakthrough Victoria
VC Fund
|
4 | Australia, United States, Philippines | Seed, Venture - Series Unknown, Series A | Health Care, Manufacturing, Biotechnology | $500k–$35M |
|
New Zealand Growth Capital Partners
VC Fund
|
4 | New Zealand, United States, Australia | Seed, Venture - Series Unknown, Series A | Software, Information Technology, Medical Device | $435k–$17M |
|
Radar Ventures
VC Fund
|
4 | Australia, United States, New Zealand | Seed, Series A, Venture - Series Unknown | Biotechnology, Robotics, Health Care | $1.8M–$30M |
|
Clean Energy Finance Corporation
VC Fund
|
4 | Australia, United States, United Kingdom | Debt Financing, Series B, Post-IPO Debt | Energy, Renewable Energy, Real Estate | $3.9M–$719M |
|
AgriZeroNZ
VC Fund
|
4 | United States, New Zealand, Sweden | Seed, Series A, Venture - Series Unknown | Biotechnology, AgTech, Animal Feed | $677k–$27M |
|
New Zealand Green Investment Finance
VC Fund
|
3 | New Zealand, Australia, United Kingdom | Debt Financing, Seed, Venture - Series Unknown | Energy, Renewable Energy, Solar | $372k–$49M |
|
University of Auckland Inventors Fund
VC Fund
|
3 | New Zealand, United States | Seed, Pre-Seed, Series A | Health Care, Biotechnology, Therapeutics | $337k–$18M |
|
Yuuwa Capital
VC Fund
|
3 | Australia | Series A, Seed, Series B | Biotechnology, Software, Analytics | $131k–$6.4M |
|
QIC BioVentures
VC Fund
|
3 | Australia | Series A | Medical, Health Care, Biotechnology | |
|
GBS Ventures
VC Fund
|
3 | United States, Australia, United Kingdom | Series B, Series A | Biotechnology, Health Care, Medical Device | $2.2M–$35M |
|
Starfish Ventures
VC Fund
|
3 | Australia, United States, Philippines | Series A, Series B | Software, Enterprise Software, Internet | $2M–$18M |
|
Powerhouse Ventures
VC Fund
|
3 | New Zealand, United States, France | Seed, Series A, Venture - Series Unknown | Software, Biotechnology, Manufacturing | $255k–$8M |
|
Vectr
VC Fund
|
3 | United States, Hong Kong, Singapore | Seed, Series A, Series B | FinTech, Financial Services, Artificial Intelligence | $950k–$70M |
|
South Australian Venture Capital Fund
VC Fund
|
3 | Australia | Seed, Series B, Series A | Health Care, Biotechnology, Internet of Things | $1M–$26M |
|
Tenacious Ventures
VC Fund
|
3 | Australia, United States, New Zealand | Seed, Pre-Seed, Series A | Agriculture, AgTech, Biotechnology | $896k–$49M |
|
Queensland Investment Corporation
VC Fund
|
3 | Australia, United States | Seed, Series A, Private Equity | Software, Information Technology, FinTech | $673k–$450M |
|
Development Bank of Wales
VC Fund
|
3 | United Kingdom, Australia, United States | Seed, Debt Financing | Software, Health Care, Manufacturing | $18k–$3.8M |
|
Tin Alley Ventures
VC Fund
|
3 | Australia, Philippines | Pre-Seed, Seed, Series B | Biotechnology, Medical, Software | $430k–$2.9M |
|
Grok Ventures
VC Fund
|
3 | Australia, United States, Singapore | Series A, Seed, Series B | Renewable Energy, Energy, Software | $808k–$151M |
|
Hostplus
VC Fund
|
3 | Australia, United Kingdom, United States | Series A, Series B, Series C | Software, Biotechnology, Semiconductor | $6.3M–$111M |
|
OneVentures
VC Fund
|
3 | Australia, United States, Israel | Series A, Debt Financing, Series B | Software, Health Care, SaaS | $1.2M–$29M |
|
Global Health Investment Fund (GHIF)
VC Fund
|
2 | United States, India, Austria | Series B, Series C | Health Care, Biotechnology, Medical Device | $4.5M–$18M |
| Access all 50 investors in Oceania Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Show more...Investment focus
- Industry: Biotechnology, Manufacturing, Health Care
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 86
- Round size: Seed $600k–$3.5M; Series A $1.6M–$16M; Series B $471k–$22M
- Lead/follow: 22% lead, 78% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- DeteQt — Semiconductor chip-based quantum magnetic field sensors using diamond - navigation, mining, medical imaging
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Plasmaleap — Plasmaleap is a plasma technology company that manufactures and sells zero-emissions chemical reactors designed for industrial and energy applications. The company develops reactor systems that use plasma processes to enable chemical production and transformation without relying on conventional combustion methods. Its technology supports sectorssuch as clean fuels, chemical manufacturing, and materials processing by offering electrified reactor solutions that can be integrated into existing industrial workflows. Plasmaleap designs modular systems that allow operators to deploy plasma reactors for on-site production and conversion of feedstocks using electricity as the primary energy input. The company also provides engineering support and technical integration services to help customers incorporate its reactor technology into commercial operations. Through its plasma-based approach, Plasmaleap focuses on enabling chemical processes that align with decarbonization and emissions reduction objectives across multiple industries.
Brandon Capital invests in the most promising biomedical opportunities that have the potential to improve the lives of patients.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: Australia, United Kingdom, United States
Investor stats
- Total investments: 79
- Round size: Seed $673k–$9.7M; Series A $5.2M–$81M; Series B $6.4M–$68M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $210M in 2019
Portfolio highlights
- Longas — Longas Technologies, a Next Generation Sequencing (NGS) technology developer, has provided details on its Morphoseq™ library prep and associated software technology at the ‘Sequencing, Finishing and Analysis.
- Myricx Bio — Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases.
- Cincera Therapeutics — Cincera Therapeutics is a privately held biotechnology company.
Uniseed is Australia's first, and longest running, university owned venture fund. Established in 2000, we are owned by 9 universities plus CSIRO (behind over 60% of Australia's research) and fund deep-tech spinouts through to global scale.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Series A, Seed
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 57
- Round size: Seed $381k–$4.2M; Series A $1.3M–$16M
- Lead/follow: 12% lead, 88% follow
- Last fund: May invest from a new fund soon — raised $14M in 2017
Portfolio highlights
- BioScout — Welcome to BioScout, your partner in revolutionizing the agriculture industry with cutting-edge automated disease detection technology for crop growers and viticulture.
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Morse Micro — Morse Micro is a fast-growing wireless integrated circuit solutions company that is reinventing Wi-Fi for the Internet of Things (IoT). The company was founded by Wi-Fi pioneers and innovators, Michael De Nil and Andrew Terry, joined by the original Wi-Fi inventor Prof. Neil Weste and wireless industry veterans, whose teams designed Wi-Fi chipsinto billions of smartphones. Headquartered in Australia with offices in China and the U.S., Morse Micro’s strong and diverse system team, portfolio of IP and patents, enables Wi-Fi HaLow connectivity across the complete IoT ecosystem, from surveillance systems and access control to industrial automation and mobile devices, allowing connected devices to reach farther. www.morsemicro.com
Artesian Capital Management is an alternative investments management company, which was spun out of ANZ Banking Group's capital markets business in 2004, with backing from ANZ Private Equity. Artesian's founding partners, purchased ANZ's stake in 2005. The company has subsequently been fully owned by partners and staff. Since 2004,Artesian has managed specialised funds focused on credit arbitrage and relative-value strategies across global financial markets. In 2008, while continuing to manage credit relative value investment strategies from its New York, London and Singapore offices, Artesian began to make principal investments in seed/early-stage ventures from its offices in Sydney, Melbourne and Shanghai. In 2011, Artesian launched the first of its early stage venture capital funds and now manages AUD +255m. Artesian's VC strategy is to partner with best of breed accelerators, incubators, angel groups and university programs. In 2017, Artesian launched its China VC Fund with a USD 50m cornerstone investment industry super fund Hostplus. Artesian will soon launch a Southeast Asia VC Fund.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Pre-Seed
- Geography: Australia, United States, Hong Kong
Investor stats
- Total investments: 407
- Round size: Seed $101k–$5M; Pre-Seed $70k–$1M; Series A $2.3M–$15M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- LivedCX® — LIVEDCX: Advanced AI technology for contact centre leaders who must simplify complexity to create growth.
- Andromeda Robotics — At Andromeda, our personalised robot companions are helping Australian aged care teams bring joy and connection to residents to improve wellbeing.
- Infiction labs — SPARC 1.2 is a solar panel robotic cleaning system designed and developed by Infiction Labs Pvt Ltd for commercial solar plants.
Icehouse Ventures is an early-stage venture capital firm. We exist to back the world's bravest Kiwi founders, launching global companies from New Zealand.
Show more...Investment focus
- Industry: Software, SaaS, Information Technology
- Stage:Seed, Series A
- Geography: New Zealand, United States, United Kingdom
Investor stats
- Total investments: 252
- Round size: Seed $650k–$4.9M; Series A $2.5M–$19M
- Lead/follow: 17% lead, 83% follow
- Last fund: Likely still investing — raised $69M in 2021
Portfolio highlights
- Hnry — Hnry automatically pays and files all taxes for contractors, freelancers, and sole traders, so they never have to think about tax again.
- Vessev — Electric hydrofoiling vessels built for commercial use. Quiet, efficient, and better for the world.
- Wellumio — Wellumio is a medical technology company redefining the boundaries of clinical imaging. We’re fusing technology, design innovation, and medical expertise to create new diagnostic pathways that support the timely delivery of urgent stroke care.
We work with inventors who are building something hard from their unique expertise in science. These inventors are building the industries that will thrive for the decades to come. We have a unique working model to accelerate a company's pathway to scale.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Manufacturing
- Stage:Seed, Series A, Series B
- Geography: Australia, United States, Philippines
Investor stats
- Total investments: 130
- Round size: Seed $1M–$7M; Series A $4.5M–$30M; Series B $13M–$72M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — raised $303M in 2023
Portfolio highlights
- Varden — FILM-FREE BARRIER COATING
- Andromeda Robotics — At Andromeda, our personalised robot companions are helping Australian aged care teams bring joy and connection to residents to improve wellbeing.
- Gilmour Space Technologies — Gilmour Space is a rocket company in Australia that is developing and launching low-cost small satellite launch vehicles. All orbits, all planets: https://www.gspacetech.com
Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed
- Geography: Australia, United Kingdom, United States
Investor stats
- Total investments: 28
- Round size: Series A $1.3M–$13M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- MycRx — MecRx is a drug development company that works on new treatments for cancer and novel mechanism of action antibiotics. Using proprietary “hit identification” technology, MecRx is developing inhibitors of cMyc, a protein that is deregulated in over 50% of all human cancers. MecRx draws on the expertise of the Peter MacCallum Cancer Centre and CSIROand is headquartered in Melbourne, Australia.MecRx was founded in 2013 by an ex-pharma/biotech team. MecRx is run as a virtual company based in Melbourne, Australia and its shareholders and service providers include the Peter MacCallum Cancer Institute and CSIRO. The company secured $5m Series A investment from the MRCF (www.mrcf.com.au) and CSIRO in 2015.
- Currus Biologics — Currus Biologics develops BEAT technology to advance CAR T-cell therapy for solid tumors, aiming to improve treatment outcomes in oncology.
- Cincera Therapeutics — Cincera Therapeutics is a privately held biotechnology company.
Finistere Ventures is an agricultural technology and life sciences venture capital investor. Founded in 2005, the company partners with other entrepreneurs and creative thinkers to build innovative companies that have the potential to transform modern agriculture, increase food security, improve nutrition, and enhance sustainability. Their appliedexperience as operators, and pioneering role in Ag Tech, is actively utilized to benefit its portfolio companies and Partners. Finistere has global access to the best new technologies from centers of Ag Tech excellence in the U.S., Australia, Israel, New Zealand, and Canada through its venture partner networks. Finistere’s locations in San Diego and Palo Alto, California keeps them connected to the centers of mainstream venture investment and the world’s leading innovation ecosystem.
Show more...Investment focus
- Industry: Biotechnology, Agriculture, Food and Beverage
- Stage:Series B, Series C, Series A
- Geography: United States, New Zealand, Israel
Investor stats
- Total investments: 67
- Round size: Series A $3.5M–$10M; Series B $7.5M–$45M; Series C $5M–$43M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $28M in 2021
Portfolio highlights
- POP — Strengthen your dog's immunity with Pop-Topper. Developed with top animal scientists and food innovators, our formulas leverage clinically proven superfoods to reduce inflammation and promote longevity. Backed by science, our daily meal topper seamlessly integrates into your dog's routine for optimal health benefits.
- Animol Discovery — Animol is building its own pipeline of break-through proprietary veterinary small molecules led by a team of animal health industry experts with vast experience in bringing drugs to market. With our unique and powerful technology platform we deliver innovative medicines that are specifically designed for the needs of veterinary patients.
- Berkeley Yeast — Better yeast for better beer. Make cleaner tasting beer with ultra low diacetyl strains, brew non alcoholic beer that tastes more like actual beer, or unlock bright grapefruit and passionfruit notes with the cleanest thiol yeast.
Callaghan Innovation is a stand-alone Crown Entity established on 1 February, 2013. Their role hasn’t previously existed in New Zealand.When they succeed, all New Zealanders will benefit from a stronger economy, higher value exports, more productive and sustainable resource use, more jobs and higher incomes.International evidence showsadvanced technology institutes like Callaghan Innovation have been successful at helping businesses build innovation capability that contributes to their growth and the broader economy.
Show more...Investment focus
- Industry: Manufacturing, Software, Information Technology
- Stage:Grant, Seed, Pre-Seed
- Geography: New Zealand, Australia, United States
Investor stats
- Total investments: 1834
- Round size: Seed $581k–$1M; Grant $5.7k–$98k; Pre-Seed $607k–$716k
- Lead/follow: 99% lead, 1% follow
Portfolio highlights
- Scanabull — Scanabull is a 3D vision to measure cattle live weight quickly and accurately, reducing handling stress and giving farmers, agents, and processors clear, real‑time weight data. It makes weighing easy, analysis simple, and sharing seamless for everyone who relies on live weight or carcass weight decisions.
- Wallo Pay — Wallo Pay, incorporated in July 2023, is a New Zealand-based fintech startup transforming digital payments for consumers and businesses. Operating across Aotearoa and with plans to expand into Australia, our founder-led team is building a B2C and B2B payments platform powered by banking APIs, enabling direct, real-time account-to-accounttransactions. By bypassing traditional card networks, Wallo Pay slashes merchant service fees from 1.5–2.5% to 0.6% or less, potentially saving New Zealand businesses $700M annually. Our product suite includes a Consumer Mobile App with QR-based and unique digital ID based payments, a Business Mobile App, and a Business Web Portal, targeting retail, hospitality, and other businesses accepting payments from end customers.Aligned with New Zealand’s Consumer Data Right (2025), Wallo Pay’s open API infrastructure empowers developers, fintech startups, and public agencies to build innovative solutions, from loyalty programs to interoperable transport payments. Our platform fosters an inclusive ecosystem, enabling business of all sizes and innovators to participate in the digital economy with low-cost, scalable payment tools. Since starting MVP development in June 2024, Wallo Pay is gearing up for an alpha pilot in Q3–Q4 2025, driving transparency, affordability, and trust in Aotearoa’s payment landscape.
- Forever Harvest — We are an Aotearoa New Zealand based cellular horticulture company, partnering with food & beverage manufacturers to develop new fruit & nut food solutions.
Stoic VC is an early-stage venture fund backing founders at the forefront of University Innovation. We partner with Uniseed to accelerate the commercialisation of university research across the ANZ.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Seed, Series A
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 24
- Round size: Seed $600k–$4.2M; Series A $7.6M–$16M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Ena Respiratory — Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs.
- Lenexa Medical — Lenexa Medical is an Australian based MedTech company.
- Kinoxis Therapeutics — Developing novel therapeutics for social dysfunction and substance use disorders.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investing in great people solving hard problems to create a better future.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Seed, Venture - Series Unknown, Pre-Seed
- Geography: New Zealand, Australia, United States
Investor stats
- Total investments: 52
- Round size: Seed $900k–$5M; Pre-Seed $511k–$1.6M; Venture - Series Unknown $3.2M–$5.5M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Regen — We send daily recommendations to our farmers' phones based on their own farm data, so NZ can farm smarter.
- Androgenix —
- Navi Medical Technologies — Navi Medical Technologies is a medical device development company.
Investing in scalable science and deep tech start-ups in Aotearoa NZ. We operate venture capital funds that invest in science and deep tech through a hands-on, active approach.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Seed, Pre-Seed, Series A
- Geography: New Zealand, Australia, United States
Investor stats
- Total investments: 20
- Round size: Seed $473k–$2.2M; Pre-Seed $337k–$972k; Series A $2.3M–$25M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Advemto — Advemto is the manufacturer and developer of ultrafast spectroscopy systems that help researchers.
- Inhibit Coatings — Inhibit Coatings is a New Zealand based company developing novel antimicrobial and antifouling coatings.
- Captivate Technology — Captivate Technology company operates a clean-tech carbon capture platform. The platform enables cement manufacturers, geothermal power plants, and biogas producers to reduce pollution and contribute to environmental initiatives by using a metal-organic framework for CO2 adsorption as a solid-state material.
Melbourne Angels is the most active startup investor in Victoria, one of the most active in Australia. Investing in start-ups since 2007, Melbourne Angels is committed to helping innovative founders build the next generation of our economy.
Show more...Investment focus
- Industry: Biotechnology, Software, Information Technology
- Stage:Seed, Angel
- Geography: Australia, United States, New Zealand
Investor stats
- Total investments: 48
- Round size: Seed $34k–$1.3M; Angel $219k–$918k
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- Emanda — Thinking about selling your business in Australia? Emanda guides you through every step: business valuation, health check, corporate compliance, and sale process. Start with a business valuation.
- Auric Essentials — Auric - The Power of Scent. Revolutionise your well-being with Auric. Discover our state-of-the-art AI-powered AromaSphere diffuser and app, designed to personalise your aromatherapy experience.
- Bitwise Agronomy — Bitwise Agronomy uses AI to analyze crop video footage and provide growers with insights into crop health, growth, and yield potential.
Invest in exclusive and pre-vetted startups, late-stage companies, and top tier funds - private market access made simple, transparent, and institutional-grade.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series B, Series A, Seed
- Geography: Israel, United States, New Zealand
Investor stats
- Total investments: 309
- Round size: Seed $593k–$10M; Series A $5.3M–$34M; Series B $8M–$65M
- Lead/follow: 16% lead, 84% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- N.Light — N.Light is a Metaverse 3D design software that allows individuals to effortlessly turn their ideas into reality.
- Hemispheric — Hemispheric develops fundamental AI technologies aimed at deciphering brain activity for innovative applications.
- MUV Interactive — MUV Interactive designs and develops innovative technology for active human sensing, providing a natural and fluent interactive experience with any type of digital application, from displayed content, and smart home appliances to IOT (Internet of Things) devices, drones and AR/VR applications. The company’s flagship product, Bird, is anintuitive device that is worn on the index finger, which transforms any space into a 3D Interactive Environment. Bird is the first device to integrate the entire spectrum of input and control methods – including touch, remote touch, gesture control and mouse functionality. This gives users the flexibility to interact with each type of digital content in the most intuitive way, whether up close or from a distance of up to 100 feet away.
Investing in the deep science and technology that can propel humanity towards a radically better future.
Show more...Investment focus
- Industry: Biotechnology, Software, Artificial Intelligence
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 274
- Round size: Seed $1M–$11M; Series A $6.2M–$47M; Series B $10M–$110M
- Lead/follow: 42% lead, 58% follow
Portfolio highlights
- Onavo — Onavo, founded 2010, is the company behind Onavo Insights, the largest mobile intelligence service, and the developer of the award-winning Onavo mobile utility apps.Onavo Insights market intelligence data, powered by fully anonymized data from Onavo's apps, powers business decisions in companies in verticals diverse as finance, gaming,entertainment and social networking, and reports are cited regularly in the press as the primary barometer of the mobile app ecosystem.
- Magisto — Magisto online video editor is a fast & powerful video maker. Turn your photos and video clips into video stories with Magisto movie editor. Start free!
- Corephotonics — Corephotonics is the pioneer and worldwide market leader of dual camera technologies for smartphones and mobile devices, providing a perfect mobile camera photography experience, novel photography features and superior image quality
Flying Fox Ventures is an early stage investment firm that invests across industry and across the micro-stages of pre-seed and seed.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A, Pre-Seed
- Geography: Australia, New Zealand, United States
Investor stats
- Total investments: 112
- Round size: Seed $662k–$3.2M; Pre-Seed $120k–$3M; Series A $649k–$11M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- Operata — Continuously measure performance to deliver the best possible customer experience.
- SPEC Toolbox — Structural timber design software for Australian engineers. Design CLT, GLT, and connections to AS1720 standards. Start your free trial and automate today.
- Teacher’s Buddy — Create lesson plans, worksheets, assessments, and more in minutes. AI-powered tools designed for educators.
K1W1 provides startups and businesses in New Zealand with early and later-stage venture investments.
Show more...Investment focus
- Industry: Software, Manufacturing, Artificial Intelligence
- Stage:Seed, Series A
- Geography: New Zealand, United States
Investor stats
- Total investments: 116
- Round size: Seed $734k–$4.1M; Series A $520k–$18M
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- Linca — Critical metals for a circular battery supply chain
- Hyades — Hyades is an AI-powered hyperspectral intelligence platform that offers soil and land insights.
- Appetise — MenuAid is a cheaper, flexible and more sustainable alternative to meal-kit delivery providers. We provide Kiwis with a weekly meal plan, complete with recipes and a list of ingredients that can either be self-shopped or collected/delivered from your favourite supermarkets.
Connecting startup business owners with angel investors to raise capital . Access a network of expertise and investment opportunities.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Angel
- Geography: New Zealand, United States, United Kingdom
Investor stats
- Total investments: 134
- Round size: Seed $306k–$4.3M; Angel $229k–$651k
- Lead/follow: 9% lead, 91% follow
- Last fund: May invest from a new fund soon — raised $12M in 2019
Portfolio highlights
- Linca — Critical metals for a circular battery supply chain
- Wellumio — Wellumio is a medical technology company redefining the boundaries of clinical imaging. We’re fusing technology, design innovation, and medical expertise to create new diagnostic pathways that support the timely delivery of urgent stroke care.
- Scanabull — Scanabull is a 3D vision to measure cattle live weight quickly and accurately, reducing handling stress and giving farmers, agents, and processors clear, real‑time weight data. It makes weighing easy, analysis simple, and sharing seamless for everyone who relies on live weight or carcass weight decisions.
We're a global dairy nutrition company owned by 10,000 farmers and their families, united by a fundamental belief in the power of dairy to make a difference.
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Wellness
- Stage:Seed, Pre-Seed, Series B
- Geography: New Zealand, United States, Germany
Investor stats
- Total investments: 16
- Round size: Seed $581k–$724k; Pre-Seed $151k–$612k; Series B $10M–$17M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Vivici — Our mission is to meet the world's growing need for sustainable, nutritious and great tasting animal-free proteins.
- DNAiTECH — At DNAiTECH we develop innovative portable isothermal amplification instruments for point of care diagnostics, in-field applications, and rapid DNA testing.
- POP — Strengthen your dog's immunity with Pop-Topper. Developed with top animal scientists and food innovators, our formulas leverage clinically proven superfoods to reduce inflammation and promote longevity. Backed by science, our daily meal topper seamlessly integrates into your dog's routine for optimal health benefits.
Formed in late 2006, the Brisbane Angels Pty Ltd is a large group of private investors who actively invest in early stage technology companies, usually in South East Queensland, Australia. The members are typically active or semi-retired former senior business executives, who apart from financial input can provide much needed value adding toinvestee companies through hands-on management experience and high level business networks.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Pre-Seed, Series A
- Geography: Australia, United States, New Zealand
Investor stats
- Total investments: 81
- Round size: Seed $250k–$1.5M; Pre-Seed $200k–$1.4M; Series A $2M–$19M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Giftbee — Giftbee reshapes gifting for businesses and consumers. Send gifts with flexibility to accept, swap, or give forward. Manage gifting programs, reduce waste, and create meaningful impact.
- Indi — Indi supports parents’ mental well-being and helps them advocate for their children’s health.
- Ovum — Meet Ovum, the intelligent health journal mobile app designed for womankind.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Your guide to finding and using government services.
Show more...Investment focus
- Industry: Software, Biotechnology, SaaS
- Stage:Seed, Series A, Angel
- Geography: New Zealand, United States, Japan
Investor stats
- Total investments: 36
- Round size: Seed $428k–$1.2M; Angel $400k–$4.3M; Series A $1.4M–$8.8M
- Lead/follow: 8% lead, 92% follow
Portfolio highlights
- MAPTO — Bringing industries together since 2008, Mapto.com stands as the premier platform for a global business directory. Serving millions of companies and suppliers worldwide.Mapto, the “Business Development Guide,” has been specially designed to offer an e-commerce solution that brings together all companies in the world and provides an excellent B2Cuser experience without sacrificing B2B functionality. The most significant difference from other marketplaces is that it is customer-supported!In today’s world, product, manufacturer, and communication demands are the basis of e-commerce searches on the internet. It restructures the “roadmap of e-commerce” by bringing all these demands together and making them accessible to users.
- Insite AI — The chosen partner by executives in RGM, insights, and I.T. to grow revenue and market share. Learn how CPGs win in pricing, assortment, trade and more.
- Surgical Design Studios — The Insides Company is the leading provider of chyme reinfusion solutions for intestinal failure
Medical Angels is the premier medical and health-specific angel investment syndicate, comprised of over 1,000 clinicians from across Australia. In 2026, we
Show more...Investment focus
- Industry: Health Care, Medical, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: Australia, Hong Kong, Singapore
Investor stats
- Total investments: 19
- Round size: Seed $7k–$1.7M; Series A $3.3M–$3.5M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- GXE — At GXE, our mission is to build the all-in-one platform for unlisted assets and funds management. We provide investors, fund managers, and family offices with the tools they need to succeed and enable them to focus on their portfolios and investors whilst GXE takes care of everything else. A licensed financial services company, GXE holdsAustralian Financial Services Licence 460870 issued by the Australian Securities and Investments Commission. GXE welcomes clients across sectors including corporate, family offices, pension and superannuation fund managers, private equity, property, and venture capital.
- Graphics et al. — Graphics et al. is a software that offers to create graphic designs. Graphics et al. mission is to make scientific communication easier.
- Clean Slate Clinic — We are a for-purpose healthcare company focused on helping Australians keen to detox from alcohol, safely from home.
Sydney Angels is a not-for-profit angel investment membership organisation. Since our establishment in 2008, they have stayed true to our mission of supporting the early-stage ecosystem by running processes and events that connect our investing members with promising early-stage companiesThey believe that encouraging smart investment in startupcompanies will benefit both our members’ portfolios and Australia’s emergent innovation economy.They see this as the ultimate win-win situation. Sydney Angels is led by an elected committee of ten volunteers who meet weekly. It is supported by an operations manager and alliance partners.
Show more...Investment focus
- Industry: Software, SaaS, Health Care
- Stage:Seed, Angel, Pre-Seed
- Geography: Australia, United States
Investor stats
- Total investments: 97
- Round size: Seed $120k–$1.5M; Angel $130k–$1.1M; Pre-Seed $337k–$1.5M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — last raise in 2016
Portfolio highlights
- Keeyu — keeyu. is a B2B SaaS platform that continuously monitors e-commerce transactions from payment to delivery. Should any issue emerge, our system immediately notifies the customer service team, enabling proactive issue resolution before it impacts the customer, saving them from opening a support ticket. The result is an enhanced post-purchaseexperience, ensuring sales retention and reducing customer complaints.Founded in 2023, the company is headquartered in Sydney, Australia, and is dedicated to empowering businesses to deliver exceptional post-purchase experiences.
- iiShield — iiShield aims to improve patient outcomes and surgeon training in transplant surgery by providing effective organ heat protection.
- Mary Technology — Generate detailed chronologies from documents in minutes with Mary Technology. Achieve 90%+ time reduction and ensure 99%+ accuracy. Try for free.
Auckland University's commercialisation arm
Show more...Investment focus
- Industry: Health Care, Medical Device, Manufacturing
- Stage:Seed, Pre-Seed, Venture - Series Unknown
- Geography: New Zealand, United States, United Kingdom
Investor stats
- Total investments: 28
- Round size: Seed $694k–$5M; Pre-Seed $283k–$1.3M; Venture - Series Unknown $3.2M–$8.4M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- RosterLab — RosterLab goal is to automate every part of the rostering process for healthcare.
- Avasa — Avasa is a medical device company. It helps to improve surgical procedures by developing novel implantable devices.
- Zenno Astronautics — Zenno Astronautics hardware and software products ensure satellite missions are effectively managed, guaranteeing maximum economic returns and responsible use of space.
IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Therapeutics
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Australia
Investor stats
- Total investments: 206
- Round size: Seed $393k–$8.5M; Series A $2.4M–$30M
- Lead/follow: 21% lead, 79% follow
- Last fund: May invest from a new fund soon — raised $125M in 2014
Portfolio highlights
- Eight19 — Eight19, located in Cambridge, UK, develops and manufactures plastic photovoltaics for energy harvesting, for the internet of things and for off-grid applications. Through the innovative use of industry-standard, high-volume, roll-to-roll processes and solution-based organic photoactive materials, the company has a highly cost-effective route forscaling-up its technology to supply the largest markets. Eight19 is currently producing modules on a small scale for commercial partners with applications in indoor energy harvesting for wireless sensor and controllers, signage and display, and outdoor power for portable electronics. Our plastic PV modules benefit from flexibility, thinness, light-weight and robustness.
- Slamcore — Positioning, mapping and perception | State-of-the-art visual SLAM turns sensor data into actionable, spatial understanding for your vehicles.
- Oxa — Autonomous Vehicle Software - Any Vehicle, Any Place, Any Time
Ip Group Australia build and support outstanding intellectual property-based companies.
Show more...Investment focus
- Industry: Biotechnology, Manufacturing, Renewable Energy
- Stage:Seed, Series A, Pre-Seed
- Geography: Australia, New Zealand
Investor stats
- Total investments: 15
- Round size: Seed $1.3M–$2.3M; Pre-Seed $811k–$896k; Series A $3M–$30M
- Lead/follow: 47% lead, 53% follow
Portfolio highlights
- MGA Thermal — MGA Thermal, specialists in thermal energy storage technology. Renewable, high-power, economical, modular, safe and sustainable thermal storage solutions.
- Additive Assurance — Additive Assurance offers quality assurance for metal additive manufacturing.
- Jetra Therapeutics — Jetra Therapeutics develops new treatment for obesity-related liver disease designed to reduce stress in liver cells.
Booster is an investment manager, superannuation and default KiwiSaver scheme provider. We offer ethical, New Zealand and specialist investment options.
Show more...Investment focus
- Industry: Biotechnology, Manufacturing, Medical Device
- Stage:Seed, Pre-Seed, Venture - Series Unknown
- Geography: New Zealand, United States
Investor stats
- Total investments: 20
- Round size: Seed $473k–$4.3M; Pre-Seed $157k–$972k; Venture - Series Unknown $158k–$6.1M
- Lead/follow: 5% lead, 95% follow
Portfolio highlights
- Linca — Critical metals for a circular battery supply chain
- Wellumio — Wellumio is a medical technology company redefining the boundaries of clinical imaging. We’re fusing technology, design innovation, and medical expertise to create new diagnostic pathways that support the timely delivery of urgent stroke care.
- Wych Limited — Wych puts your financial health back in your control.
Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: Germany, United States, Australia
Investor stats
- Total investments: 170
- Round size: Seed $1.5M–$10M; Pre-Seed $586k–$3.5M; Series A $9.7M–$47M
- Lead/follow: 5% lead, 95% follow
Portfolio highlights
- Mkind — Mkind builds intelligent robots for high-mix manufacturing, developing advanced automation solutions that can adapt to diverse production requirements, improve operational efficiency, and support manufacturers in handling complex, low-volume, and frequently changing product lines.
- Orbem — Transform biological imaging with AI-powered MRI technology. Non-invasive solutions for poultry, fruits, nuts, and health. Building a sustainable future.
- Transition Metal Solutions — Transition harnesses wild microbial communities to recover copper and other critical metals from low-grade mining resources.
The Breakthrough Victoria Fund is a $2 billion investment by the Victorian Government to drive investment in research and innovation.
Show more...Investment focus
- Industry: Health Care, Manufacturing, Biotechnology
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: Australia, United States, Philippines
Investor stats
- Total investments: 55
- Round size: Seed $708k–$6.8M; Series A $4M–$35M; Venture - Series Unknown $500k–$30M
- Lead/follow: 53% lead, 47% follow
Portfolio highlights
- AlleSense — AlleSense has developed a unique and novel solution to label-free imaging, the NanoMslide.
- Mental Jam — We are a games studio dedicated to creating impactful experiences that explore mental health.
- Deftbiotech — Deftbiotech is a biotech startup developing peptide-based antifungal treatments for nail and skin infections.
The New Zealand Growth Capital Partners (formerly New Zealand Venture Investment Fund) was established to support early-stage technology companies and to stimulate private investment into this space.
Show more...Investment focus
- Industry: Software, Information Technology, Medical Device
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: New Zealand, United States, Australia
Investor stats
- Total investments: 81
- Round size: Seed $694k–$4.9M; Series A $3.5M–$17M; Venture - Series Unknown $435k–$6.1M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Linca — Critical metals for a circular battery supply chain
- Wellumio — Wellumio is a medical technology company redefining the boundaries of clinical imaging. We’re fusing technology, design innovation, and medical expertise to create new diagnostic pathways that support the timely delivery of urgent stroke care.
- Scentian Bio — Scentian Bio operates as a platform that provides ultimate sensing solution.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Radar Ventures operates as an venture capital firm.
Show more...Investment focus
- Industry: Biotechnology, Robotics, Health Care
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Australia, United States, New Zealand
Investor stats
- Total investments: 21
- Round size: Seed $1.8M–$11M; Series A $3.2M–$15M; Venture - Series Unknown $19M–$30M
- Lead/follow: 5% lead, 95% follow
Portfolio highlights
- Acumino — Acumino offers next-generation, AI powered robot models for the execution of highly dexterous tasks in industrial automation settings. The Acumino AI is trained on the most accurate data of robot interactions and facilitates the deployment of next-generation intelligent robot workers in a fast, scalable, reliable, cost-efficient manner, unlockingunmatched dexterity & ROI.
- OncoRes Medical — OncoRes Medical develops an imaging technology to provide intraoperative information available to surgeons to assist with the identification of tumor and healthy tissue.OncoRes Medical is an early-stage medical device company located in Perth, Western Australia and is developing the patent-protected technology in collaboration with leadingresearchers at the University of Western Australia and the Harry Perkins Institute of Medical Research and breast cancer surgeons at the Western Australian public health system.With funding provided by the Medical Research Commercialisation Fund (MRCF), OncoRes Medical aims to develop the technology for use in clinical applications that require the real-time assessment of tissue microstructure.
- Diag-Nose.io — Antibiotic resistance is rising to dangerously high levels in all parts of the world threatening our ability to treat common infectious diseases. Diag-Nose is working on a novel diagnostic tool to non-invasively distinguish between viral,bacterial and allergy-mediated sinusitis.
The Clean Energy Finance Corporation invests using a commercial approach to overcome market barriers and mobilize investment in renewable energy, energy efficiency, and low emissions technologies. They seek to catalyze and leverage private sector funding for the commercialization and deployment of clean energy technologies necessary for thetransition to a carbon-constrained economy.
Show more...Investment focus
- Industry: Energy, Renewable Energy, Real Estate
- Stage:Debt Financing, Series B, Post-IPO Debt
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 137
- Round size: Series B $3.9M–$77M; Post-IPO Debt $42M–$719M; Debt Financing $18M–$511M
- Lead/follow: 42% lead, 58% follow
- Last fund: May invest from a new fund soon — raised $62M in 2018
Portfolio highlights
- FlexiGroup — At FlexiGroup, we love to connect customers with things that will help them work and play. FlexiGroup is a diversified financial services group. Through a network of over 16,000 retail and business partners we provide a wide range of innovative finance products and payment solutions to consumers and businesses. From supporting education, toequipping a home, to building a business – we have a wide range of solutions to help. This includes interest free cards and no interest ever payment plans; consumer and business leasing solutions; and mobile and broadband plans. FlexiGroup operates in Australia, New Zealand and Ireland, and is offered at more than 16,000 locations including Harvey Norman, Escape Travel, IKEA, Domayne, Joyce Mayne, King Living, Nick Scali, Australian Outdoor Living, JB Hi-Fi, AGL Solar, The Good Guys Kitchens, Noel Leeming, Husqvarna, and the Fantastic Group.
- Relectrify — Unlocking extra lifetime and performance of batteries via advanced battery management (BMS) technology.
- Quintessential Equity — Owner-operator discipline across acquisition, improvement and operations. Tenant-first execution, governed decision-making and clear reporting for wholesale and professional investors. Explore the portfolio, capabilities and how we invest across cycles.
A world-first public-private partnership helping farmers reduce emissions while maintaining profitability and productivity.
Show more...Investment focus
- Industry: Biotechnology, AgTech, Animal Feed
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: United States, New Zealand, Sweden
Investor stats
- Total investments: 16
- Round size: Seed $677k–$10M; Series A $7M–$27M; Venture - Series Unknown $3M–$14M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- Rumin8 — Rumin8 - Solving livestock methane emissions
- Ruminant BioTech — Ruminant BioTech is a company that creates slow-release devices for long-term controlled-release methane mitigation.
- Āmua Innovation — Āmua Innovation specializes in developing solutions for pasture-based farming to lead natural food production.
New Zealand Green Investment Finance provides support to the growth of innovative energy and carbon management.
Show more...Investment focus
- Industry: Energy, Renewable Energy, Solar
- Stage:Debt Financing, Seed, Venture - Series Unknown
- Geography: New Zealand, Australia, United Kingdom
Investor stats
- Total investments: 29
- Round size: Seed $3.1M–$7.6M; Debt Financing $644k–$49M; Venture - Series Unknown $372k–$3.2M
- Lead/follow: 24% lead, 76% follow
Portfolio highlights
- ESP — ESP is an energy solution provider.
- Carbn Group — Carbn Group is a car fleet management company that makes car fleet services sustainable and accessible to more users.
- Ruminant BioTech — Ruminant BioTech is a company that creates slow-release devices for long-term controlled-release methane mitigation.
University of Auckland Inventors Fund
Show more...Investment focus
- Industry: Health Care, Biotechnology, Therapeutics
- Stage:Seed, Pre-Seed, Series A
- Geography: New Zealand, United States
Investor stats
- Total investments: 9
- Round size: Seed $2.2M–$2.5M; Pre-Seed $337k–$972k; Series A $1.4M–$18M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- TamoRx — TamoRx’s founding inventors have discovered a novel biological mechanism within cells that restricts the immune system from fighting cancer. The research team is focused on developing a new therapy that frees patients’ immune systems from this restriction to increase immune attack on cancer cells within tumours offering a new hope for a broad rangeof cancer patients. TamoRx aims to develop small molecule inhibitors that work both as a single agent and in combination with other treatments, increasing the applicability of immunotherapy for patients.
- Opo Bio — Opo Bio develops cell lines for the cultivated meat industry and researchers.They are building a multi-species and multi-cell type product bank for research and commercial usage. They are creating infrastructure that will enable the industry to progress and more effectively scale.
- Luminoma — Luminoma will enable easy access to objective and precise skin cancer screening. With Luminoma, clinicians can confidently discern malignant from benign, reducing unnecessary referrals and biopsies.
Yuuwa Capital is a $40M early-stage venture capital firm based in Perth, Western Australia. They are actively seeking outstanding investment opportunities where Yuuwa can provide both capital and expertise to help founders, management and early investors to turn good ideas into great companies.
Show more...Investment focus
- Industry: Biotechnology, Software, Analytics
- Stage:Series A, Seed, Series B
- Geography: Australia
Investor stats
- Total investments: 16
- Round size: Seed $131k–$808k; Series A $979k–$4.2M; Series B $2.6M–$6.4M
- Lead/follow: 63% lead, 37% follow
Portfolio highlights
- Nexgen Plants — Healthy plants, healthy people, living planet. Nexgen develop's plants for future generations that will improve the environment and health of future generations.
- Icetana — icetana Motion Intelligence dramatically improves the active monitoring of security surveillance networks, with AI video anomaly detection and video analytics.
- Agworld — Plan your crop, mitigate your risks, improve your profitability with Agworld farm management software.
QIC BioVentures, previously known as Queensland BioCapital Funds, was established by the Queensland Investment Corporation (QIC) in October 2002 as its venture capital arm specialising in biotechnology. Like any other QIC Fund, QBF's purpose is to maximize investment returns for QIC's clients. QBF does not provide grants or other formsof assistance.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A
- Geography: Australia
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Verva Pharmaceuticals — Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined productportfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need.Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy.
- Protagonist Therapeutics — Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs.
Founded in 1996, GBS invests in young businesses developing and commercialising products which, when combined with the right management and finance, will make a significant difference to patients' lives and deliver financial returns for their investors. Their areas of particular interest and expertise include human healthcare, biotechnologyproduct development and life science start-ups. In particular, recent investments have included biological or small molecule therapeutics, medical devices and diagnostics.GBS invests in private or public companies whether at start-up or later stages of company development. Their investors include major Australian superannuation funds.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical Device
- Stage:Series B, Series A
- Geography: United States, Australia, United Kingdom
Investor stats
- Total investments: 41
- Round size: Series A $2.2M–$9M; Series B $8.8M–$35M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- Ivantis — Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development forthe treatment of other debilitating diseases within ophthalmology.
- Moximed — Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis.
- Elastagen — Elastagen is a clinical stage medical company with an advanced pipeline of products based on the human protein tropoelastin, a pioneering medical biomaterial. Elastin is a critical component of tissues in the human body which require the ability to stretch and recoil, such as the skin, lungs, arteries, elastic ligaments. Elastagen hasdeveloped a synthetic version of the elastin protein which is identical to that naturally present in the human body. Elastagen’s platform technology has potential applications in a number of areas including skin rejuvenation, scar remodelling and tissue repair. Elastagen was founded following the acquisition of intellectual property rights to the elastin technology which was developed by Prof Weiss at the University of Sydney. The Company has since successfully attracted capital from a number of leading Australian and overseas life science venture capital groups. Elastagen’s operations have expanded from its Australian base to include production in Europe and clinical operations in the UK.
Starfish Ventures is an Australian venture capital firm focused on information technology, life sciences, and clean technology companies.
Show more...Investment focus
- Industry: Software, Enterprise Software, Internet
- Stage:Series A, Series B
- Geography: Australia, United States, Philippines
Investor stats
- Total investments: 57
- Round size: Series A $2M–$6.6M; Series B $2.5M–$18M
- Lead/follow: 49% lead, 51% follow
- Last fund: May invest from a new fund soon — raised $134M in 2008
Portfolio highlights
- CAP-XX — CAP-XX makes ultra-thin, high-power supercapacitors for portable and compact devices. Ideal for energy storage. Quotes & samples available.
- Milkdrop — Introducing The Milkdrop Breast Pump Cushion. A Super Soft Silicone Cushion That Attaches To Your Breast Pump and Gently Moulds to Your Breast Making Pumping More Comfortable.
- Smart Urban Properties Australia (SUPA) — Smart Urban Properties Australia (SUPA) offers a unique range of property solutions by bringing together renewable energy and mobility, super-speed fiber, and smart prop-tech. It is formed by bringing together Epsilon Security, b.energy, Fibrecorp, Smart Automation Systems, and connecX.
powerHouse is a New Zealand intellectual property commercialisation company investing to develop new spin-out ventures
Show more...Investment focus
- Industry: Software, Biotechnology, Manufacturing
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: New Zealand, United States, France
Investor stats
- Total investments: 12
- Round size: Seed $2.1M–$7.9M; Series A $255k–$7M; Venture - Series Unknown $921k–$8M
- Lead/follow: 8% lead, 92% follow
Portfolio highlights
- VeriQuantix — VeriQuantix was spun out of the University of Queensland. VeriQuantix is an Australian startup specializing in cybersecurity, focusing on quantum technology to enhance the security of optical fiber communication networks. Their core innovation, Quantum Link Verification (QLV), is designed to detect and alert network operators to physical tappingattempts and intercept cyber attacks on fiber optic networks. This technology leverages quantum principles, specifically entangled photons, to verify the trustworthiness of network links by ensuring that any unauthorized access disrupts photon entanglement and triggers immediate alerts.
- Granular Energy — Granular Energy provides solutions for managing and trading clean energy. We are the leading provider of energy certificate management software for utilities, helping to streamline certificate managment processes and enabling utilities to launch next-generation green offers, including transparency down to the hourly level.
- Liquid Instruments — Redefining the way scientists, engineers, students, and professionals experience test and measurement with Moku software-reconfigurable hardware platforms
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Vectr is a venture firm based in Hong Kong. They combine investment, creation and growth to deliver game-changing impact to teams ready to tackle global issues, transform industries and improve the lives of millions.That combines capital, creation and partnership to deliver game-changing impact. We strive to be the ideal partner for founders thatare building transformation products and looking to expand their businesses into asia.
Show more...Investment focus
- Industry: FinTech, Financial Services, Artificial Intelligence
- Stage:Seed, Series A, Series B
- Geography: United States, Hong Kong, Singapore
Investor stats
- Total investments: 79
- Round size: Seed $950k–$6.5M; Series A $1M–$37M; Series B $12M–$70M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Percent — Unlock private credit investments with Percent. Access alternative investments on the platform powering the future of private markets.
- Micro Connect — Micro Connect provides market infrastructure, fintech, and platform development.
- MasterExchange — Trading platform for music rights leveraging emerging technology to create friction free and compliant investment opportunities to everyone.
South Australian Venture Capital Fund - helping build dynamic and innovative South Australian startups / scaleups and accelerate their growth to a national and global scale.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Internet of Things
- Stage:Seed, Series B, Series A
- Geography: Australia
Investor stats
- Total investments: 13
- Round size: Seed $1M–$12M; Series A $2.3M–$20M; Series B $13M–$26M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Seonix Bio — Seonix Bio is dedicated to helping health professionals, individuals and researchers understand glaucoma risk using genetics.
- Pearler.AI — Pearler gives your team super powers to respond fast to RFP, RFI, RFQ, Security, Cyber, Risk & Grant Questionnaires.
Tenacious Ventures - Australia's first and only dedicated agrifood tech VC firm.
Show more...Investment focus
- Industry: Agriculture, AgTech, Biotechnology
- Stage:Seed, Pre-Seed, Series A
- Geography: Australia, United States, New Zealand
Investor stats
- Total investments: 24
- Round size: Seed $1.1M–$10M; Pre-Seed $896k–$2.2M; Series A $5.9M–$49M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Nbryo — Contact Us for interest: contact@nbryo.com
- Agovor — Agovor - Robotic towing machines to boost productivity while reducing your environmental footprint.
- SwarmFarm Robotics — Global crop protection specialists ADAMA and Australian ag-tech company.
Queensland Investment Corporation is an investment company.
Show more...Investment focus
- Industry: Software, Information Technology, FinTech
- Stage:Seed, Series A, Private Equity
- Geography: Australia, United States
Investor stats
- Total investments: 29
- Round size: Seed $673k–$10M; Series A $3.6M–$10M; Private Equity $239M–$450M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $17M in 2022
Portfolio highlights
- ModnPods — B2B modular manufacturing platform for multi-storey & hybrid developments across QLD & NSW. Backed by McNab. Accelerate builds by 50%.
- Pacific Energy — Our innovative energy solutions are transforming the way power is generated, delivered, and managed across the nation.
- Gilmour Space Technologies — Gilmour Space is a rocket company in Australia that is developing and launching low-cost small satellite launch vehicles. All orbits, all planets: https://www.gspacetech.com
Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.
Show more...Investment focus
- Industry: Software, Health Care, Manufacturing
- Stage:Seed, Debt Financing
- Geography: United Kingdom, Australia, United States
Investor stats
- Total investments: 248
- Round size: Seed $360k–$3.3M; Debt Financing $18k–$3.8M
- Lead/follow: 60% lead, 40% follow
- Last fund: May invest from a new fund soon — raised $25M in 2018
Portfolio highlights
- Wagonex — Car subscription is the new, all-inclusive, flexible alternative to leasing. No large downpayment and a single fixed monthly payment. Just add fuel and go.
- Jehu Group — The Jehu Group is a third generation family owned business with over 80 years of successful trading history.We mange our operations on a day-to-day basis through three trading subsidiaries. Each subsidiary is supported by Jehu Group Limited which provides finance, HR, technical and procurement functions.In all of our markets, we position ourselvesas a dynamic and bespoke alternative to national contractors and house builders and are proud of our strong reputation in the market place.
- Reacta Biotech — Reacta Biotech has been established to develop, manufacture and commercialise oral food challenge materials to pharmaceutical standards of Good Manufacturing Practice (GMP).
Tin Alley Ventures collaborates with companies and researchers in the University of Melbourne's ecosystem to invest in & support world-changing businesses.
Show more...Investment focus
- Industry: Biotechnology, Medical, Software
- Stage:Pre-Seed, Seed, Series B
- Geography: Australia, Philippines
Investor stats
- Total investments: 7
- Round size: Pre-Seed $430k–$2.9M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- i14 — We are i14 — we sit at the intersection of Computational Cognitive Science and AI research, and have developed a new class of models called Laplace Sequence Models that are an order of magnitude faster and more efficient and multiples more accurate than the transformer. We’ve also built a foundation model platform that allows organisations tocreate private, domain-specific expert models deployable across any environment (on-prem, at the edge, on device, in a private cloud, or hosted by i14). Our research lab continues to push beyond many of the limitations of current AI, and has a host of research projects which are continually integrated to update our foundation model platform. We recently closed a $4M initial round and are preparing for the next round.
- Mirugen — Mirugen is a preclinical biotechnology company (re)programming cells to unlock innate cellular repair mechanisms.
- Kronus — Full-stack development infrastructure for safety-critical systems.
Backing a better tomorrow
Show more...Investment focus
- Industry: Renewable Energy, Energy, Software
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, Singapore
Investor stats
- Total investments: 69
- Round size: Seed $808k–$10M; Series A $3.3M–$63M; Series B $26M–$151M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- Endolith — Endolith is a biotech company transforming sustainable mining by leveraging microbes, synthetic biology, and cloud computing to extract more critical minerals like copper from low-grade ores. Working with the many of the leading mining companies, Endolith is advancing its innovative technology to commercial scale. Recognized as a finalist in theBHP Unearthed BioMetals cohort and a member of the Alaska Critical Minerals Collaborative, Endolith is driving the future of mining with sustainable, efficient, and responsible solutions for the clean energy transition.
- MAKO — Solving human problems with nature’s surfaces.
- Asterix Foods — Asterix Foods is a biotechnology company designed to build protein production using plant-cell culture techniques. The company's platform is developing and growing bioactive proteins for food that are scalable, functional, and complex, enabling users with plant cell-cultured and animal-free proteins.It was founded in 2022 and is located inTel Aviv, Israel.
Join our leading Australian superannuation fund, committed to putting our members first, with a low admin fee and strong returns. Become a member today!
Show more...Investment focus
- Industry: Software, Biotechnology, Semiconductor
- Stage:Series A, Series B, Series C
- Geography: Australia, United Kingdom, United States
Investor stats
- Total investments: 63
- Round size: Series A $6.3M–$49M; Series B $20M–$111M; Series C $13M–$60M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- Emesent — Solutions for GPS-denied environments - delivering revolutionary efficiency, safety and operational insights to underground mining and other industries.
- Gradiant — Gradiant is a solutions provider and developer of cleantech water projects for advanced water and wastewater treatment. They provide microelectronics, pharmaceuticals, food and beverage, lithium and key minerals, and renewable energy.
- Gilmour Space Technologies — Gilmour Space is a rocket company in Australia that is developing and launching low-cost small satellite launch vehicles. All orbits, all planets: https://www.gspacetech.com
OneVentures is a later-stage venture capital firm focused on scaling Technology and Healthcare companies through growth equity and credit. The firm's role extends far beyond investment, as the firm actively guides companies toward achieving their next critical milestones. By leveraging decades of global experience and operational expertise,OneVentures accelerates growth and helps shape the future of its portfolio companies.A global growth focus drives their investment selection, with their current portfolio including companies with truly innovative products tackling multi-billion-dollar problems, from needle-free vaccinations to virtual communications to adaptive e-learning.
Show more...Investment focus
- Industry: Software, Health Care, SaaS
- Stage:Series A, Debt Financing, Series B
- Geography: Australia, United States, Israel
Investor stats
- Total investments: 84
- Round size: Series A $1.5M–$23M; Series B $13M–$29M; Debt Financing $1.2M–$14M
- Lead/follow: 44% lead, 56% follow
- Last fund: Likely still investing — raised $145M in 2022
Portfolio highlights
- me&u — me&u is an online ordering and payment application designed to order meals. They provide communication technology to order and pay through mobile phones at restaurants. Their process of ordering with waiters and splitting bills that enable users to order their food and pay bills through a digital payment platform.
- Truescope — Make better informed communications decisions with Truescope. Harnessing millions of media posts every day to deliver you real-time information that influences your business strategy.
- Vertero — Axial Therapeutics is a biotechnology company fundamentally changing the treatment of neurological diseases and disorders by harnessing groundbreaking science in the microbiome-gut-brain axis.
The Global Health Investment Fund (GHIF) is a $108 million social impact investment fund designed to provide financing to advance the development of drugs, vaccines, diagnostics and other interventions against diseases that disproportionately burden low- and middle-income countries. GHIF supports late-stage innovations for public health challengessuch as malaria, pre-eclampsia, cholera, HIV and river blindness, with an emphasis on infectious diseases and maternal/infant health issues that cause significant morbidity and mortality in resource-limited settings. GHIF may also make investments that improve or expand access to existing products—such as developing pediatric formulations of approved therapeutics or improving the stability of widely-used global health vaccines.As an investment fund with a limited time-horizon, GHIF seeks opportunities that have a high probability of successful commercialization within two or three years. Products with “dual market” potential are of greatest interest; i.e., those that will have a clear impact on public health in developing countries but also have value in high-income countries. High-volume / low-margin products, such as essential vaccines, are also of significant interest.GHIF employs a range of investment structures including mezzanine debt, convertible debt, preferred equity and project financing with an average investment target of approximately $10 million per project. Each GHIF project must advance the Fund’s social impact objectives and demonstrate the ability to achieve commercial success.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series B, Series C
- Geography: United States, India, Austria
Investor stats
- Total investments: 18
- Round size: Series B $7.5M–$18M; Series C $4.5M–$14M
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — raised $108M in 2012
Portfolio highlights
- PATH — We are a global team of innovators working to accelerate health equity so all people and communities can thrive.
- CXL Ophthalmics — CXLO is developing a minimally invasive treatment for an ectatic corneal disease that can bring early intervention to millions of patients globally.
- Themis Bioscience — Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing andacquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech Investors in Oceania investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 investors investing in Oceania Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!